Kck Ltd. Purchases Shares of 5,270,845 NeuroPace, Inc. (NASDAQ:NPCE)

KCK LTD. bought a new position in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,270,845 shares of the company's stock, valued at approximately $58,981,000. NeuroPace makes up 78.7% of KCK LTD.'s holdings, making the stock its biggest holding. KCK LTD. owned 17.66% of NeuroPace at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of NPCE. Bank of New York Mellon Corp bought a new stake in NeuroPace in the second quarter valued at $257,000. Rhumbline Advisers bought a new position in NeuroPace in the 2nd quarter valued at $111,000. XTX Topco Ltd raised its position in shares of NeuroPace by 56.1% during the second quarter. XTX Topco Ltd now owns 24,055 shares of the company's stock worth $182,000 after acquiring an additional 8,643 shares during the last quarter. Millennium Management LLC boosted its holdings in NeuroPace by 13.3% in the second quarter. Millennium Management LLC now owns 686,037 shares of the company's stock valued at $5,186,000 after acquiring an additional 80,324 shares during the last quarter. Finally, Financial Advocates Investment Management boosted its holdings in NeuroPace by 20.0% in the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company's stock valued at $125,000 after acquiring an additional 3,000 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors.

NeuroPace Trading Up 0.5 %

NPCE traded up $0.06 during mid-day trading on Friday, hitting $11.97. The stock had a trading volume of 83,546 shares, compared to its average volume of 57,575. The stock's fifty day simple moving average is $10.82 and its 200-day simple moving average is $8.40. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The firm has a market capitalization of $357.30 million, a price-to-earnings ratio of -11.97 and a beta of 2.02. NeuroPace, Inc. has a 1-year low of $5.45 and a 1-year high of $18.15.

NeuroPace (NASDAQ:NPCE - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $21.06 million during the quarter, compared to analysts' expectations of $19.33 million. During the same quarter in the prior year, the company earned ($0.28) earnings per share. As a group, research analysts forecast that NeuroPace, Inc. will post -1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on NPCE. JPMorgan Chase & Co. boosted their price target on shares of NeuroPace from $9.00 to $14.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 17th. Wells Fargo & Company reduced their price target on NeuroPace from $15.00 to $13.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, NeuroPace presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.00.

Insider Transactions at NeuroPace

In other NeuroPace news, major shareholder Ltd. Kck sold 223,991 shares of the stock in a transaction on Friday, October 25th. The shares were sold at an average price of $5.45, for a total value of $1,220,750.95. Following the completion of the sale, the insider now owns 5,270,845 shares in the company, valued at $28,726,105.25. This trade represents a 4.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 227,858 shares of company stock valued at $1,244,328 over the last 90 days. 22.20% of the stock is owned by corporate insiders.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.